Iotasulis a triiodoaminoisophthalic acid derivative patented by Schering A.-G. as a water-soluble contrast medium. Iotasul is very suitable for subepidermal infusion (indirect lymphography) for the demonstration of small (initial) dermal lymphatics in the macro-range (precollectors). By this method, normal lymph vessels can be demonstrated in the healthy skin of hands and feet which are so fine that they cannot be punctured for direct lymphography.

Pirepolol is the beta-adrenergic blocking agent. It was developed as an antihypertensive agent.

Octimibate is a non-prostanoid inhibitor of platelet aggregation that acts via the prostacyclin receptor.

Gliamilide is a high-potency sulfamylurea hypoglycemic agent. It has been found to be well tolerated in humans and displays a very short plasma half-life. Like sulfonylureas, gliamilide can lower blood glucose levels by increasing the insulin release from pancreatic beta cells.

Spiclamine (Epsilamine) is a hemostatic agent. It was administered to a total of 23 patients with urological diseases, including 8 postoperative cases. Marked effective, effective and ineffecgive responses were observed in 8, 10 and 5 cases respectively, making 78.3 % of effectiveness. In cases of so-called essential renal bleeding and prostatic disease, a particularly beneticial result was obtained making 93.3 % of marked effectiveness. No serious side effects was seen in all cases treated.

Glyprothiazol (VK 57 or RP 2254) is a sulfonamide derivative. This compound lowers blood glucose levels by increasing the release of insulin from the pancreas. It stimulates insulin secretion through a direct action on pancreatic islets. Glyprothiazol was the first of oral hypoglycemic sulfonamides used in the treatment of type 2 diabetes mellitus.

Halocortolone, a synthetic glucocorticoid that was used as a vasoconstrictor, but was never marketed

Azepexole (or previously known as B-HT 933), a selective alpha 2-adrenoceptor agonist that was studied for the man with physiological tremor. It was shown that the drug produced sedation compared to placebo but not when compared to pre-treatment values. Some studies also have revealed the anti-tussive and antihypertensive properties of azepexole.

Pimetremide is a spasmolytic agent.

Atiratecan (previously known as CH4556300 or TP300), the prodrug of a topoisomerase 1 inhibitor, CH0793076. Atiratecan has been studied in phase II clinical trials to treat cancers (e.g., colorectal cancer; gastric cancer; esophageal cancer), but these studies were suspended.